



SARS-CoV-2 & Influenza A/B Multiplex Assay

Offering our clients state-of-the-art testing is part of CPL's ongoing commitment to excellence.

Effective October 7, 2020, Clinical Pathology Laboratories (CPL) will offer the Roche cobas® SARS-CoV-2 & Influenza A/B multiplex assay. The Roche assay is the first in the US to be authorized under the FDA's Emergency Use Authorization process. The assay uses highly sensitive high-throughput real-time RT-PCR technology for simultaneous detection and reporting of SARS-CoV-2 (the causative agent of COVID-19), influenza A, and/or influenza B in upper respiratory specimens. Nucleic acid from one or more of these organisms may be detectable in respiratory specimens during the acute (symptomatic) phase of a viral illness, and testing for SARS-CoV-2 specifically should be offered to individuals suspected of a respiratory viral infection consistent with COVID-19 by a healthcare provider.

As the US heads into the fall, CPL is pleased to offer simultaneous testing for influenza and COVID-19 associated viruses out of a single collection. In the 2019-2020 flu season, the CDC estimates that 39-56 million Americans contracted flu, and more than 400,000 required hospitalization. The Johns Hopkins Coronavirus Resource Center reports close to 7 million COVID-19 cases since January 2020 with daily cases recently peaking at approximately 70,000/day in the US. According to the American Society of Microbiology, coinfection with multiple respiratory viruses is possible. More importantly, both COVID-19 and influenza are spread by virus-laden respiratory droplets; both infect lower and upper respiratory epithelium; and both cause fever, cough, anosmia and other respiratory symptoms. However, these do not share the same anti-viral therapy, availability of vaccine or implications for public health. Distinction between these viruses may be clinically highly important. Further test details are given below.

Please contact your Account Representative should you have any questions.

| | |
|---|--|
| Order Code / Test Name: | 3571 COVID19/Influenza A/B, NAAT |
| Collection Site: | Nasopharyngeal (NP; healthcare provider collected (HCP)), nasal mid-turbinate swab (HCP or self-collected), anterior nares (HCP or self-collected) |
| Collection Media: | Viral transport media (UVT, UTM-RT, M4-RT, others), 0.9% saline and phosphate buffered saline (PBS) |
| Transport Temperature: | Refrigerated |
| Stability (collection to initiation of testing): | 48 Hours Room Temperature; 72 Hours Refrigerated; 1 Week Frozen (-20 Degrees); 1 Month Frozen (-70 Degrees) |
| Performed: | Sunday through Saturday |
| Analytic Time: | 1 - 3 Days |
| Methodology: | Real-Time Polymerase Chain Reaction (RT-PCR) |
| CPT Codes: | 87636 |

References:

<https://coronavirus.jhu.edu/map.html>

<https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm>

<https://asm.org/Articles/2020/July/COVID-19-and-the-Flu>

Thank you for supporting Clinical Pathology Laboratories